WORCESTER, Mass., Nov. 5, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (NasdaqCM:GNBT - News) announced today that the first prostate cancer patients had been treated with its novel peptide vaccine in a Phase I clinical trial. The trial is being conducted as an extension of a collaborative agreement between Generex’s Antigen Express division and the Saint Savas Cancer Hospital. The Laikon Hospital, University of Athens will also function as a site for the trial.
